XTL Biopharmaceuticals Receives Nasdaq Delisting Notice Over Delayed Annual Report

On May 22, 2026, XTL Biopharmaceuticals Ltd. announced it received a Staff Delist Determination letter from Nasdaq on May 18, 2026. The notice was issued because the company failed to timely file its Annual Report on Form 20-F for the fiscal year ended December 31, 2025, violating Nasdaq Listing Rule 5250(c)(1). This filing delinquency serves as an additional basis for delisting, as XTL is already under review by the Nasdaq Hearings Panel for failing to meet the minimum $2.5 million stockholders’ equity and $1.00 bid price requirements. The company has until May 26, 2026, to present its views to the Panel and request a stay of the suspension of its securities from The Nasdaq Capital Market. XTL intends to request an extension of the stay by the deadline. However, there is no guarantee that the Panel will grant the stay or allow the company’s continued listing. XTL Biopharmaceuticals is an IP portfolio company focused on treatments for Lupus and Sjögren’s Syndrome.